ANI Pharmaceuticals Inc. (NASDAQ:ANIP) dropped 2% during trading on Friday . The company traded as low as $60.01 and last traded at $60.22, with a volume of 126,118 shares trading hands. The stock had previously closed at $61.42.

ANIP has been the subject of a number of research analyst reports. Guggenheim reiterated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of ANI Pharmaceuticals in a research note on Saturday, May 7th. Standpoint Research cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 24th. Raymond James Financial Inc. began coverage on ANI Pharmaceuticals in a research note on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 price objective for the company. Zacks Investment Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 6th. Finally, Citigroup Inc. cut ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 price objective for the company. in a research note on Friday, July 8th. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $64.00.

The company has a 50 day moving average of $63.14 and a 200-day moving average of $49.30. The company has a market cap of $689.23 million and a PE ratio of 70.34.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.34. During the same period in the previous year, the firm earned $0.55 earnings per share. The company had revenue of $31.30 million for the quarter, compared to analyst estimates of $27.63 million. The company’s revenue for the quarter was up 60.5% compared to the same quarter last year. On average, equities research analysts predict that ANI Pharmaceuticals Inc. will post $4.12 EPS for the current year.

In related news, VP Robert W. Schrepfer sold 12,500 shares of the business’s stock in a transaction on Monday, August 8th. The stock was sold at an average price of $67.06, for a total transaction of $838,250.00. Following the completion of the transaction, the vice president now directly owns 17,362 shares of the company’s stock, valued at approximately $1,164,295.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Arthur Przybyl sold 37,455 shares of the business’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $66.97, for a total value of $2,508,361.35. Following the transaction, the insider now directly owns 200,788 shares of the company’s stock, valued at $13,446,772.36. The disclosure for this sale can be found here.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.